VEXAS Syndrome
Conditions
Keywords
VEXAS syndrome, MAS825, Arumakimig, somatic mutation, ubiquitin-like modifier activating enzyme (UBA1), glucocorticoid taper, vacuoles, E1 Enzyme, Autoinflammatory, Arthritis, arthralgia
Brief summary
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Detailed description
This is a randomized, double-blind, placebo-controlled study with a 52-week duration evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids. Participants will be randomized 1:1 to either arumakimig or placebo. Following the double-blind period, participants may have the option to enter a 2-year (104-week) open-label extension (OLE) period, continuing until Week 156. A 16-week safety follow-up period must be completed after the OLE (up to Week 172) or after the double-blind period (up to Week 68).
Interventions
DRUGArumakimig
Arumakimig Injection
DRUGPlacebo
Placebo Injection
Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female participants aged ≥18 years at screening. * Somatic mutation in UBA1 gene known to be associated with VEXAS. * Participants must have at least two manifestations of VEXAS at screening or in the past 6 months. * Participants must be able to start treatment for Pneumocystis jiroveci pneumonia (PJP) during the study if indicated according to the local guidelines. * Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study.
Exclusion criteria
* Participants meeting any of the following criteria are not eligible for this study: * Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant. HBsAg negative participants who are hepatitis B core antibody (HBcAb) positive are also excluded unless protocol-defined criteria are met. * Participants with a positive HCV antibody test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA must be excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible. * Active viral, bacterial, or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections. * Known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the Investigator, an HIV test can be performed locally to confirm eligibility. * Live vaccinations within a certain period prior to arumakimig treatment. Live vaccines are prohibited during the trial and up to a certain period following the last dose of arumakimig. * History of malignancy of any organ system, including post-transplant lymphoproliferative disorder (except for skin Bowen's disease, completely treated and resolved, localized squamous or basal cell carcinoma of the skin or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks, in situ cervical cancer or non-invasive malignant colon polyps that have been removed), treated or untreated, within a protocol-defined period, regardless of whether there is evidence of local recurrence or metastases. * History of or current hepatic disease (moderate to severe Hepatic Impairment as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (for Hepatitis B or C), cirrhosis or hepatic failure. * Participants of child-bearing potential who do not agree to comply with required contraceptive use as outlined in the protocol. Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52 | From baseline up to Week 52 | Response is defined as meeting both criteria: A) Clinical domain: In participants with clinical disease activity in any domain at baseline, complete resolution of clinical manifestations related to active disease in at least one affected domain. In participants with no clinical disease activity in any domain at baseline, continued absence of clinical manifestations in all domains at Week 52. AND B) Protocol-defined glucocorticoid reduction through 52 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants achieving Overall Clinical Response (OCR) at Week 52 | From baseline up to Week 52 | Achieving OCR at Week 52 is defined as meeting all the following criteria: * Absence of active inflammatory manifestations of VEXAS * Protocol-defined reduction in oral glucocorticoid. * Protocol-defined reduction in C reactive protein. |
| Number of participants achieving resolution of VEXAS manifestations | From baseline up to Week 52 | In participants with clinical disease activity in any domain at baseline, achieving complete resolution of clinical manifestations. |
| Number of participants with oral glucocorticoid reduction | From baseline up to Week 52 | Number of participants achieving protocol-defined glucocorticoid dose reduction through 52 weeks. |
| Total number of flare-free days over 52 weeks | Up to 52 weeks | Total cumulative number of days over 52 weeks meeting the protocol-defined criteria for a flare-free day. |
| Number of participants achieving Hematologic Improvement - Erythroid (HI-E) during the double-blind treatment period | From baseline up to Week 52 | Hematologic Improvement - Erythroid (HI-E) during the double-blind 52-week treatment period among participants with baseline hemoglobin within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria. |
| Number of participants achieving Hematologic Improvement - Platelets (HI-P) during the double-blind treatment period | From baseline up to Week 52 | Hematologic Improvement - Platelets (HI-P) during the double-blind 52-week treatment period among participants with baseline platelets within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria. |
| Number of participants without worsening disease according to a participant-reported questionnaire | From baseline up to Week 52 | Participants without protocol-defined worsening of disease according to a participant-reported questionnaire. |
| Time to death during the double-blind treatment period | Up to 52 weeks | Assessment of mortality through Week 52 in each treatment arm. |
| Number of participants with adverse events (AEs) and serious adverse events (SAEs) | Up to 172 weeks | Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms and laboratory values qualifying and reported as AEs. |
Contacts
CONTACTNovartis Pharmaceuticals
Outcome results
None listed